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Depressive symptoms in persons with acute coronary syndrome: 
specific symptom scales and prognosis 
 
Objective 
To determine which particular depressive symptom scales, derived from three 
scales, predicted poorer prognosis in persons with acute coronary syndrome 
(ACS). 
Methods 
Hospitalised ACS patients (n=408) completed questionnaires (depression, 
vital exhaustion). Mokken scaling derived unidimensional scales. Major 
cardiac events (cardiac mortality, ACS, unplanned revascularisation) were 
assessed at median 67 weeks post-event. 
Results 
Only depressive symptoms of fatigue-sadness predicted prognosis in 
univariate (hazard ratio [HR]=1.8, 95% CI 1.1–3.0, p=0.025) and multivariate 
analysis (HR=1.8, 95% CI 1.1–2.9, p=0.025). Symptoms of anhedonia 
(HR=1.6, 95% CI 0.9–2.8, p=0.102) and depressive cognitions (HR=1.3, 95% 
CI 0.7–2.2, p=0.402) did not. 
Conclusion 
Symptoms of fatigue-sadness, but not other symptoms, were associated with 
increased risk of major cardiac events. Depression should be considered as a 
multidimensional, rather than a unidimensional, entity when designing 
interventions. 
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Introduction 
Depression has been consistently associated with a two-fold risk of recurrent 
cardiac events or mortality in those with coronary heart disease (CHD),1-3 yet 
the treatment of depressive symptoms does not improve prognosis.4,5 
However, depression is a very heterogeneous construct, and there may be 
little symptom overlap among those labelled as ‘depressed’. For example, one 
person could experience depressed mood, anergia, substantial weight 
variation, sleep variation and psychomotor retardation/agitation; and another 
could report anhedonia, worthlessness/guilt, impaired concentration, 
indecisiveness or difficulty thinking, or suicidal ideation. Yet, assuming that 
other criteria are also met, both would be labelled with the diagnosis ‘major 
depressive disorder’, according to DSM-IV.6 Therefore, when researchers 
state that depression is associated with poorer cardiovascular prognosis, it is 
appropriate to ask whether specific symptoms are more associated with 
poorer prognosis than others.7,8  
 
Previous research has suggested that particular depressive symptoms may 
be more pertinent for prognosis than others.7,9-12 Doyle et al.12 compared the 
HADS depression subscale (HADS-D; n=316) and the fast-screen 7-item 
version of the Beck Depression Inventory (which does not assess 
somatic symptoms – BDI-FS; n=282) in independent groups of patients 
with acute coronary syndrome (ACS). At one year, those who were 
depressed according to the HADS-D, which concentrates on anhedonia, had 
a significantly increased risk of all-cause mortality, while those scoring above 
the threshold on the BDI-FS did not. The authors concluded that anhedonia 
may be particularly cardiotoxic, but that the single anhedonia item on the BDI-
FS may not be powerful enough to detect risk. Unfortunately, due to the 
assessment of independent samples, the scales could not be directly 
compared through latent variable analytic techniques.  A factor analysis of the 
BDI in 2466 patients with myocardial infarction found two main factors 
comprising cognitive/affective symptoms, and somatic/affective symptoms.10 
Only the somatic/affective factor was predictive of poorer prognosis over a 
mean of 2.5 years. These findings are difficult to interpret for a number of 
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reasons. Somatic symptoms may be confounded by coronary disease, 
treatment or comorbidity factors, and these symptoms are not required 
for a diagnosis of major depression except in terms of number of 
symptoms. Therefore, using total scores on depression scales may 
indicate those who report symptoms akin to depression, but who do not 
endorse the core diagnostic symptoms – and who should therefore be 
regarded as false positives. Thus, it could be argued that if depression 
really predicts prognosis, then the core diagnostic symptoms of 
depression – depressed mood, anhedonia,6 and anergia13 – should be 
predicting outcomes. However, the symptom of depressed mood 
(sadness) loaded on both factors in the analysis by de Jonge et al.10  
described above, rendering interpretation of the findings difficult.14 
Indeed, this criticism can be made of factor analysis in general, which 
allows items to cross-load during latent variable analysis. Another 
problem with factor analysis is that binary items may lead to bias for 
which non-specialist statistical software does not adjust, and it may also 
be affected by extremely skewed distributions,15,16 such as typically 
found with BDI items. Therefore, alternative latent variable methods 
should be used to derive specific unidimensional symptom scales from 
aggregated data.  
 
In sum, the use of heterogeneous depression scales and symptoms,7 and 
reliance on factor analytic techniques, may limit research pinpointing 
cardiotoxic symptoms of depression. The present study aims to replicate and 
extend previous findings,12 using different depression scales to predict 
prognosis. We included a measure of ‘vital exhaustion’ (symptoms of fatigue 
and demoralisation which are unrelated to cardiovascular disease severity, 
and which are argued to be independent of depression17,18), to assess the 
core depressive symptom of anergia.13 The aims of the present paper were 
therefore: 
1) to replicate previous findings12 and to determine whether certain scales 
were better prognostic predictors, or more generally whether scoring above 
threshold on any scale predicted prognosis 
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2) to derive specific symptom scales in order to predict prognosis. We 
hypothesised that specific symptom scales would be derived, reflecting the 
core symptoms of depressed mood, anhedonia, and fatigue, along with 
another scale indicative of depressive cognitions (low self-esteem, 
worthlessness). 
 
Method 
Study design and participants 
A prospective cohort study design was used to determine the association of 
depressive symptoms with major adverse cardiovascular events (MACE) - a 
combination of cardiovascular mortality, recurrent ACS or unplanned 
revascularisation. Non-cardiac mortality was omitted. Ethical approval was 
obtained. As scoring above cut-off on two of the scales was previously 
demonstrated to be associated with poorer prognosis,12 patients’ medical 
teams or general practitioners were informed if patients scored above the 90th 
percentile of normative data. Across 12 participating hospitals, consecutive 
patients with confirmed ACS were invited to participate in the survey. Staff 
could choose not to recruit a participant if they deemed the patient to be too 
distressed.19 Each centre was awarded a nominal fee (€10) per patient 
recruited, which was paid to the relevant Coronary Care fund. Relevant 
medical risk factors were collated for each participant. Medical records were 
accessed one year after recruitment. Patients were recruited from 
January 2006 to September 2007, with final chart access in September 
2008. 
 
Measures 
Hospital Anxiety and Depression Scale – Depression subscale (HADS-D) 
The HADS-D is a 7-item depression scale,20 with an optimal threshold score 
of >7,21-23 which was adopted in the present study. The HADS-D has an 
average sensitivity and specificity of approximately 0.80 for the identification 
of major depression.22 
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Beck Depression Inventory – Fast Screen (BDI-FS) 
The BDI-FS is a 7-item scale that focuses on cognitive symptoms of DSM-IV 
criteria,24,25 with a recommended cut-off score of >3 that yields a sensitivity of 
>0.90 and specificity of >0.85 for detecting major depressive disorders.26,27 
We omitted the suicidality item of the BDI-FS as it was not predictive of one-
year mortality outcomes in unpublished analyses from a previous study, and 
did not correlate well with other scale items.12 Also, the suicidality question 
may be considered intrusive by patients, thus lessening the likelihood of a 
response.28 Thus, a 6-item BDI-FS was used with the recommended 
threshold (>3) maintained. 
 
Maastricht Questionnaire – 10 item (MQ-10) 
The brief 10-item version of the Maastricht Questionnaire (MQ-10) was used 
as a measure of anergia.29 The scale items are scored as binary (yes=1, 
no=0). The recommended cut-off (>4) was used. Predictive validity has been 
reported previously.29 
 
Co-morbidities 
Major co-morbidities were recorded and recoded as per the Charlson 
Comorbidity Index (CCI).30,31 To prevent subsequent multicollinearity with 
variables assessed separately (i.e. history of MI, heart failure diabetes), a 
second, modified CCI total score was generated omitting these items.  
 
Statistics 
Mokken scaling 
Mokken scaling is a non-parametric, iterative scale-building technique, 
suitable for skewed and binary items. It is based on Guttman scaling, 
which forms a unidimensional, ordinal scale of binary items along a 
continuum. Thus, a positive response to one particular item indicates 
which of the other items have also been answered positively. For 
example, if someone indicates that they are ‘very depressed’ (the most 
‘difficult’ item), they should also have endorsed the less extreme 
choices of ‘somewhat depressed’ and ‘moderately depressed’. Mokken 
scaling is a stochastic version of Guttman scaling which can also use 
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polytomous items, and uses Loevinger’s H statistic as an indicator of 
scale fit.32 The H-value represents [1 – (observed Guttman 
errors/predicted Guttman errors)]. Observed Guttman errors are the 
number of times a ‘mistake’ is made by respondents as items are 
endorsed as if not in an ordered sequence, and expected Guttman 
errors are the probability that the items are chosen by chance. Thus, a 
co-efficient of ≤.5 represents a scale with items at a maximum 50% 
Guttman error rate. By convention, 0.3≥c<0.4, 0.4≥c<0.5 and c≥0.5 
indicate weak, moderate and strong scales respectively. To derive 
specific symptom scales, a recommended procedure was followed.16 It 
was expected that a high co-efficient (approximately c>0.5) would be 
required, and only such results are presented. Mokken scale analysis 
was conducted using a procedure written for Stata SE 9.233 by Jean-
Benoit Hardouin.34 
 
Generating scale scores for derived symptom scales 
To generate total scale scores in the present study, all items within any scales 
with binary items were collapsed into binary (e.g. for the fatigue-sadness 
scale 79% of participants endorsed a score of zero on the BDI-FS item, this 
item was collapsed by recoding the other options as 1). This allowed the items 
to be totalled. For the anhedonia scale, all items were 4-point options, so this 
was totalled. These adjustments had negligible impact on the overall scale 
Loevinger H co-efficient (data not shown), indicating that no precision was 
lost. In order to directly compare the effect sizes of the derived scales in 
prognostic analyses, these were then divided into top quartiles (1) and other 
(0). 
 
Missing data 
Missing data was imputed using regression techniques, which compares very 
favourably with other missing data techniques.35 Missing data on scale items 
were calculated from other scale items, age and sex. For example, if a 
participant did not answer BDI-FS item 3, the score was imputed from the 
following variables (BDI-FS items 1, 2, 4, 5, 6, age, sex). Imputation ranged 
from 1-10% for all items. 
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Multi-site cluster sampling 
Analysis was conducted using robust variance estimation commands to 
account for original clustering of patients within hospitals. Patients in the same 
hospital will be more similar – i.e. correlated – than patients randomly 
sampled from the entire population. This leads to underestimation of standard 
errors and confidence intervals and a greater than 5% rate of type I errors. 
Huber-White robust variance estimation adjusted standard errors (and 
therefore confidence intervals and significance tests) for the homogeneity 
introduced by cluster sampling.  
 
Multivariate predictors of MACE 
Odds-ratios (ORs) were elicited using logistic regression when comparing 
those with elevated scale scores to those without. Cox regression was used to 
elicit hazard ratios (HRs) for event occurrence. To prevent overfitting, a 
restricted multivariate model was required, dependant on the number of 
MACE.36 In order to manually build a multivariate model, non-psychometric 
variables which predicted endpoints with a p-value <.15 were included in a 
multivariate model (age, sex, smoking, diabetes, history of CHD, history of 
revascularisation, length of hospital stay, left ventricular function <40%). 
Incomplete data was available for employment status, and this variable was 
therefore omitted. Variables which had a p-value >0.5 were immediately 
deleted. After this, any covariate with a p-value <.15 was retained. Age was 
initially analysed as a continuous variable. However, further investigation 
showed that there was clear evidence of a threshold effect for survival. Those 
over 65 years of age were at increased risk, but younger age categories did 
not differ (data not shown). Age was therefore used as a categorical variable 
(over 65 years versus younger). Psychometric variables were then added to 
this multivariate model. 
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Results 
Study participation 
In terms of demographic variables, there was no difference in age, sex, 
having private health insurance, or working status between those who 
responded to the questionnaire when compared to those who did not (data 
not shown). 
 
Sample profile 
Of the 505 eligible patients invited to participate, 430 completed the 
composite questionnaire (85% response rate), and scaling analysis was 
conducted on all 430 questionnaires (Fig 1). Baseline risk factor, 
demographic and recurrent ACS information was available from medical 
charts of 408 participants who completed a questionnaire (95%).  
 
-------------------- 
Fig 1 here 
-------------------- 
 
Descriptive statistics [prevalence scoring above threshold (mean, 
standard deviation)] for each of the scales was as follows: HADS-D – 
11% (3.5, 3.0), BDI-FS – 24% (2.1, 2.7), MQ-10 – 43% (4.2, 2.9). Combining 
these scales, 49% (212/430) of the sample were found to have elevated 
depressive symptoms of some form.  
 
Table 1 shows the profile of the sample, comparing those who had elevated 
depressive symptoms to those who had not. Those with depression were 
more likely to be smokers, have diabetes, have a positive history of CHD and 
subsequent revascularisation, but less likely to be employed. Depressed 
persons also had slightly lower total cholesterol, but there was substantial 
missing data for employment and cholesterol. Depressed persons were also 
less likely to have experienced a cardiac arrest. No age or gender differences 
were significant, but there were trends for those with depression to be 
younger and female. 
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---------- 
Table 1 about here 
---------- 
 
Table 1 also shows univariate prognostic information for demographic, CHD 
risk factor, disease severity and co-morbidity variables. Age over 65, having a 
history of diabetes, CHD or revascularisation, having a longer hospital stay 
and having left ventricular function <40% all increased the hazard of 
endpoints. Smoking and being employed were protective of events. CCI total 
score was associated with endpoints, but the modified CCI score was not. 
 
In multivariate analysis using the described technique, the following variables 
were retained: age, sex, history of CHD and length of hospital stay (data not 
shown). 
 
Mokken scaling 
Overall, three ‘strong’ scales are derived from the data (Table 2). The first 
scale, which is 9 items, assessed a ‘fatigue-sadness’ cluster of symptoms. 
Five of the items clearly address fatigue, and are from the MQ-10. Other items 
are either ambiguous or address an element of hopelessness (MQ-10 8, 9, 7), 
or address sadness (BDI-FS 1). The sadness item was the last to join the 
scale (items towards the top of the table display the most ‘difficult’ items, i.e. 
the items least likely to be endorsed, and vice versa).  
 
The second scale clearly measures the symptom of anhedonia. That the 
single BDI-FS anhedonia item joins with these HADS-D anhedonia items 
provides this scale with good content validity. 
 
The final derived scale from the state depression items clearly assessed 
perceptions of worthlessness, pessimism and overall negative cognition. This 
scale is labelled ‘depressive cognitions’.  
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Psychometric predictors of MACE 
Original depression scales 
Univariate and multivariate analyses of the original and derived scales are 
displayed in Table 3.  
 
----------------- 
Table 3 here 
----------------- 
 
Scoring above threshold on the HADS-D was a significant predictor of 
MACE in univariate and multivariate analysis, but no other scale was 
significant. This association was not attenuated when controlling for 
other depressive symptom scales (data not shown). 
 
In order to assess whether depressive symptoms in general were predicting 
risk, data were combined. Scoring above threshold on any of the HADS-D, 
BDI-FS or MQ-10 was not associated with outcome (HR=1.2, 95% 0.7–1.9 CI, 
p=0.572). 
 
Derived depressive symptom scales 
In univariate analyses with the derived scales, only fatigue-sadness was 
predictive of outcome (Table 3). Fatigue-sadness also predicted MACE in 
multivariate analysis. However, anhedonia also predicted MACE in adjusted 
analyses. Depressive cognitions remained non-significant. When both fatigue-
sadness and anhedonia were included in the multivariate models, fatigue-
sadness predicted MACE (HR=1.8, 95% CI 1.02–3.4, p=0.045), but 
anhedonia did not (HR=1.4, 95% CI 0.8–2.3, p=0.237) (other model data not 
shown). The Kaplan-Meier survival curves for derived scales are shown in Fig 
2. 
 
------------------- 
Fig 2 here 
------------------- 
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Discussion 
The present study was the first to use Mokken scaling in ACS patients in an 
attempt to derive unidimensional, ‘pure’ symptom scales and predict 
prognosis. The study also replicated findings published previously. Results 
are discussed in terms of Mokken scaling, prognostic findings and 
implications for interventions. Although the current sample are largely 
comparable to a previous Irish cohort,12 smoking was surprisingly 
protective of MACE, which is probably accounted for by a younger age 
of presentation in smokers (data not shown). 
 
Scaling results 
Mokken scaling has been successfully used in previous research to derive 
ordinal and unidimensional scales from original questionnaires, including 
depression.16,37-39 In the present study, the items broke down into several 
specific scales, which only partially supported the hypothesised scales of 
depressed mood, anhedonia, fatigue and depressive cognitions. The first 
scale derived was labelled “fatigue-sadness”. The items in this scale clearly 
addressed fatigue, sadness and possibly the element of hopelessness. Thus, 
the first derived scale was reflective of two of the core diagnostic symptoms of 
depression, and the symptom of hopelessness which is not a requirement for 
either ICD-10 or DSM-IV criteria. The BDI-FS sadness item was the most 
‘difficult’ item to endorse in the fatigue-sadness scale, but it clustered with 
MQ-10 fatigue items throughout several analyses of varying thresholds (data 
not shown). Similar findings have been reported previously in confirmatory 
factor analyses, with fatigue and sadness loading on the same factor.10,40,41 
The rest of the scale also incorporated items which could be argued to assess 
a level of pessimistic views of the future, although overall this scale is 
indicative of fatigue. It is plausible that such symptoms would cluster together 
in a clinical setting. 
 
The next derived scale was labelled ‘anhedonia’. It consisted of three HADS-
D items (4, 2, 12) and the one anhedonia item (4) from the BDI-FS. The fact 
that the BDI-FS items scaled with the HADS-D anhedonia items gives this 
scale excellent content validity. This can be considered a ‘pure’ symptom 
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scale that assesses one of the core diagnostic symptoms of major 
depression. Thombs et al.,40 during a confirmatory factor analysis of the BDI-
II, also found evidence of a two-item ‘pure’ anhedonia factor that scaled 
separately to cognitive or somatic factors.  
 
The last scale derived supports the hypothesis of a ‘depressive cognitions’ 
scale. This consists of three BDI-FS items (5, 2, 3) and the crying item (10) 
from the MQ-10. It appears that this measures the state of thinking negatively 
about oneself and feeling bad about it. This also supports previous work 
which has shown such cognitive symptoms cluster together in cardiac 
patients.10 
 
Original depression scales and prognosis 
When analysing the scales as recommended, the HADS-D was predictive of 
MACE, but the BDI-FS was not, replicating previous research.12 Other 
prognostic research using the HADS-D has shown mixed findings.11,42-44 One 
reason for this is that the HADS-D may assess something particular in the 
Irish population, which is not assessed by other scales. The HADS-D, while 
concentrating mainly on anhedonia, also contains items which could be 
argued to assess other elements of depression. Item 8 could be argued to 
assess fatigue. This item combination may mean that, of the scales used 
here, the overall HADS-D score is the best measure of the hypothesised 
cardiotoxic symptoms.7 
 
Although the BDI-FS did not predict outcomes, an inspection of individual 
items showed that item 1 ‘Sadness’ was predictive of MACE (data not shown). 
Thus, this single item was not sensitive enough to predict outcomes when 
combined in a cluster of other items which mainly assessed depressive 
cognitions.  
 
The MQ-10 was not a predictor of MACE. This contrasts with previous 
findings, which showed that this scale was predictive of both onset of cardiac 
events and prognosis post-event in Dutch samples.29 The MQ-10 has not 
previously been validated in an Irish sample, which may explain the findings. 
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The present study also attempted to determine whether depressive symptoms 
in general were predictors of prognosis. Combining data using recommended 
thresholds showed no association with prognosis. This may partially explain 
heterogeneous findings regarding depression and prognosis,1,7 and provides 
support for the investigation of specific symptom patterns.  
 
Derived symptom scales and prognosis 
It was hypothesised that if the core symptoms of depressed mood, anhedonia, 
or fatigue predicted prognosis, then this may provide evidence of depression 
being a risk factor for clinical outcomes. The results showed that fatigue-
sadness was a significant predictor of MACE, and that this association 
survived multivariate adjustment. Poor left ventricular function has been 
hypothesised to account for the relationship between depression and 
outcomes.1 However, this variable was not significant in the present 
multivariate model, and was therefore excluded from most analyses. 
However, in analysis including left ventricular function of <40%, the 
association between fatigue-sadness and MACE was not attenuated (data not 
shown). With low left ventricular function, symptoms of fatigue would probably 
be expected. That the association is still independent of this measure 
highlights the robustness of the findings. However, these results are clouded 
somewhat by the mixing of the fatigue and sadness items, but also by the 
items from the MQ-10 which appear to measure hopelessness or pessimistic 
future views. However, no individual MQ-10 items were associated with 
MACE (data not shown). Therefore, it is unlikely that these items were driving 
the association between the fatigue-sadness scale and outcomes – this was 
more likely to be the case for the BDI-FS sadness item. Alternatively, it may 
be the clustering of sadness and hopelessness and fatigue which was 
especially cardiotoxic.45 Previous research addressing these issues has been 
inconsistent, and has used only single items to assess hopelessness.9,46 
Further research is needed to extricate these issues, and should involve 
validated hopelessness scales.  
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The somewhat ‘purer’ anhedonia measure had somewhat comparable effect 
sizes to fatigue-sadness when predicting MACE. In multivariate analysis 
anhedonia was predictive of the endpoint. However, when fatigue-sadness 
was included in the model predicting MACE, the association between 
anhedonia and outcome was non-significant. This finding suggests that the 
study did not have the power to consistently detect the association 
between anhedonia and MACE, or that anhedonia may not be as important 
as fatigue-sadness for cardiovascular prognosis. One could speculate that the 
subtype of depression characterised by anhedonia is simply less cardiotoxic 
than that characterised by fatigue-sadness. It is possible that depression 
characterised by anhedonia may have differential behavioural or physiological 
sequelae than depression characterised by fatigue or sadness.  Although 
other studies have been suggestive of associations with anhedonia and 
clinical events,11,12 no other study has been identified that has derived an 
anhedonia scale and assessed its relative predictive value in comparison to 
other symptoms.  
 
The measures used should not be confounded by assessment of other 
somatic, heterogeneous symptoms that may simply be a reflection of 
comorbidities or CHD severity. Previous studies have also addressed the 
issue of potential confounding from somatic symptoms. Thombs et al.,41 when 
predicting outcomes in 477 MI patients, used structural equation modelling to 
partial out the variance of somatic symptoms that were unrelated to 
depression, but to still maintain variance from somatic symptoms that were 
related to depression. Although the general depression factor predicted 12-
month all-cause mortality, it is unclear whether a factor without somatic 
symptoms would have predicted prognosis – de Jonge et al.10 found that such 
a factor was not associated with outcomes.  
 
Depressive cognitions were not predictive of outcomes. This finding supports 
research outlined previously.10,41 Indeed, Martens et al.47 showed that 
depressed cardiac patients demonstrate fewer such cognitions than do 
psychiatric samples. It is therefore questionable what scale items reflecting 
these depressive cognitions contribute to research in this area. It is possible 
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that, although perhaps clinically useful, these items are simply adding noise to 
data, especially total scale scores, when the primary aim is to predict 
prognosis. This would therefore question the recommendations of the 
National Heart, Lung, and Blood Institute Working Group Report on 
assessment and treatment of depression in patients with cardiovascular 
disease, which called for the use of the BDI in such research.48 The 
cumulative evidence suggests that several BDI items should be ignored when 
considering cardiovascular prognosis in future research. 
 
Limitations & Strengths 
The present study has a number of strengths and limitations. We assessed 
cardiac events only, producing results which were not inflated by non-cardiac 
events. Analyses accounted for within-site variability – a technique not 
typically used in other multi-centre studies. It is possible that patients had 
recurrent ACS, but were admitted to hospitals other than their index 
admission centre, leading to an underestimation of events. No data was 
available on possible depression treatments received post-event. Also, 
follow-up was a median of approximately 15 months. There may be different 
results over a longer period.49 The number of endpoints and danger of 
overfitting did not allow for the adjustment of all cardiovascular and 
demographic covariates,36 and therefore necessitated use of a less-
than-ideal stepwise covariate adjustment technique. 
 
Previous research has suggested that the timing of the depressive episode is 
relevant for prognosis.19,50,51 This data was unfortunately unavailable in the 
present study, and it is therefore impossible to speculate whether symptoms 
of fatigue-sadness better reflect the new-onset depression which has been 
shown to be particularly cardiotoxic in other research.  
 
It could be argued that the omission of somatic items is a weakness of the 
present study. However, such items have shown mixed results when 
predicting prognosis,10,52 and they may be confounded by coronary disease, 
treatment or comorbidity factors. Comorbidities were assessed, and did not 
account for the present findings. Future research could also assess 
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specific somatic symptoms, and compare these to other symptom 
scales when predicting prognosis. 
 
Implications for practice and interventions 
Given the failure of intervention trials to reduce depression and cardiovascular 
mortality, and increasing evidence that specific symptoms of depression are 
more cardiotoxic than others, it may be time to revisit the notion that the 
syndrome of major depression is a risk factor for poorer cardiovascular 
prognosis. The results of the present study suggest that depression is 
multidimensional, and that only some aspects of depression are relevant for 
poorer outcomes post-ACS. Furthermore, global measurements of depression 
severity could be re-considered. If specific cardiotoxic symptoms need to be 
the focus of intervention, they should be measured on several unidimensional 
scales, rather than a total score on a single multidimensional scale being 
adopted as a unidimensional variable. The adoption of multidimensional 
measures may throw more light on the results of intervention trials. This may 
be especially pertinent, given the recent findings which show that although 
tricyclic and serotonin reuptake inhibitors are equally efficacious when 
compared on total depression scale scores, they actually differ significantly in 
terms of which symptom dimensions they affect.53,54 
 
Conclusions 
In the present study, only symptoms of fatigue-sadness consistently predicted 
prognosis, whereas anhedonia and depressive cognitions did not. Specific 
symptoms of depression may need to be considered when predicting 
cardiovascular outcomes. This suggests that depression should not be 
considered as a unidimensional state, but as a multidimensional one.  
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Table 1: Demographic and risk factor profile of the current sample (n=408 
unless otherwise stated), categorised by having elevated depressive 
symptoms or not, and univariate associations with MACE 
Variable No depressive 
symptoms 
(n=209) 
Elevated 
depressive 
symptoms 
(n=199) 
OR 95% 
confidence 
interval (CI) 
HR 95% CI 
Demographic factors      
   
Age (over 65=1) 62.2 
(10.9) 
60.4 
(10.4) 0.98 0.96 1.01 
2.1*** 1.6 2.8 
Men 83% 77% 0.7 0.5 1.1 1.4 0.9 2.0 
Has a partner (1=yes) 73% 76% 1.2 0.7 2.0 0.7 0.4 1.5 
Employed (1=yes) (n=321) 28% 19% 0.6*** 0.5 0.8 0.4** 0.2 0.7 
Private health insurance 35% 28% 0.7 0.5 1.1 0.8 0.5 1.5 
Previous risk factor history         
Current smoker 27% 44% 2.2*** 1.6 2.9 0.6* 0.4 0.9 
Prior hypertension 50% 50% 1.0 0.8 1.4 1.2 0.7 2.0 
Prior diabetes 6% 15% 2.8** 1.4 5.4 1.6 1.0 2.5 
Cholesterol (mmol/l) (mean, std 
dev) (n=326) 
4.7 
(1.2) 
4.4 
(1.2) 0.8* 0.7 1.0 0.98 0.8 1.2 
Prior CHD 27% 38% 1.7** 1.2 2.4 1.9* 1.2 3.0 
Prior CAD 24% 35% 1.6** 1.1 2.4 2.0** 1.3 3.2 
Prior ACS 15% 24% 1.8* 1.1 2.7 2.0** 1.3 3.2 
Prior MI 12% 24% 2.2** 1.2 4.0 2.1*** 1.4 3.1 
Prior Angina 11% 15% 1.4 0.7 2.8 1.1 0.5 2.4 
Prior revascularisation 21% 31% 1.7* 1.1 2.6 1.3 0.9 2.0 
Prior CABG 8% 11% 1.3 0.7 2.4 1.6 0.6 3.8 
Prior PTCA 15% 23% 1.6* 1.1 2.5 1.0 0.6 1.6 
Prior Stent 11% 14% 1.2 0.8 1.9 1.5 0.9 2.5 
Current hospitalisation         
Acute antiplatelet 82% 79% 0.9 0.5 1.4 0.7 0.4 1.2 
Acute anticoagulant 66% 62% 0.8 0.6 1.2 0.9 0.6 1.4 
Thrombolysis 27% 22% 0.8 0.4 1.4 1.1 0.4 2.8 
Revascularisation received 77% 69% 0.7 0.4 1.05 0.8 0.5 1.2 
PTCA/Stent 69% 62% 0.7 0.5 1.2 0.9 0.6 1.3 
CABG 9% 9% 1.1 0.5 2.2 1.0 0.4 2.5 
Cardiac arrest confirmed 19% 12% 0.6 0.3 1.0 1.0 0.7 1.3 
Length of hospital stay (days)^ 7 (5-11) 7 (5-10) 0.99 0.97 1.02 1.03** 1.01 1.05 
Left ventricular function 
(confirmed as <40%) 16% 14% 0.8 0.6 1.2 1.4 0.8 2.4 
Diagnosis of MI 70% 72% 1.1 0.7 1.7 1.0 0.7 1.4 
Co-morbidities         
CCI total score 1 (1–2) 1 (1–2) 1.1 0.96 1.3 1.2* 1.0 1.4 
CCI modified score 0 (0–1) 0 (0–1) 1.0 0.8 1.2 1.1 0.9 1.4 
*<0.05, **<0.01, ***<0.001 
^ - 32 missings imputed with median length of stay of 7 days (no discernible difference to data) 
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Table 2: Mokken scale analysis at c(0.5) for scales hypothesised to 
break down into core depressive symptoms  
Derived symptom scales Observed 
Guttman 
errors 
Expected 
Guttman 
errors 
Loevinger 
H co-
efficient 
Scale 1: Fatigue-sadness (9-items)    
BDI-FS1 Sadness  185 388.4 0.52 
MQ10-6 Do you ever wake up with a feeling of exhaustion and 
fatigue? 196 459.8 0.57 
MQ10-8 Do you have the feeling these days that you just do not have 
what it takes anymore? 172 397.9 0.57 
MQ10-2 Do you feel listless? 171 470.7 0.64 
MQ10-1 Do you often feel tired? 80 296.1 0.73 
MQ10-9 Do you believe that you have come to a “dead end”? 57 198.5 0.71 
MQ10-3 Do you feel weak all over or without energy? 156 460.6 0.66 
MQ-10-4 Do you sometimes have the feeling that your body is like a 
battery that is losing its power? 109 376.9 0.71 
MQ10-7 Do you feel you want to give up trying? 62 216.8 0.71 
Scale 594 1632.8 0.64 
Scale 2: Anhedonia (4-items) 
      
HADS-D 4 I can laugh and see the funny side of things 167 356.1 0.53 
HADS-D 2 I still enjoy the things I used to enjoy 217 478.3 0.55 
BDI-FS 4 Loss of pleasure 185 421.3 0.56 
HADS-D 12 I look forward with enjoyment to things  207 478.4 0.57 
Scale 388 867.0 0.55 
Scale 3: Depressive cognitions (4-items) 
      
BDI-FS 5 Self-dislike 190 393.6 0.52 
MQ10-10 Do you sometimes cry or feel like crying? 121 260.8 0.54 
BDI-FS 2 Pessimism 169 373.1 0.55 
BDI-FS 3 Past failure 182 400.7 0.55 
Scale 331 714.1 0.54 
 
 
 
 
Table 3: Original and derived scales (upper quartiles) and univariate and 
multivariate associations with endpoints 
 
Univariate ^Multivariate 
Original scales HR 95% CI p HR 95% CI p 
HADS-D 2.5 1.3 4.8 0.006** 2.9 1.4 5.9 0.004** 
BDI-FS 1.2 0.6 2.2 0.644 1.3 0.7 2.5 0.467 
MQ-10 1.2 0.8 1.8 0.343 1.2 0.8 2.0 0.338 
Derived scales         
Fatigue-sadness 1.8 1.1 3.0 0.025* 2.0 1.1 3.6 0.017* 
Anhedonia 1.6 0.9 2.8 0.102 1.7 1.0 2.8 0.043* 
Depressive cognitions 1.3 0.7 2.2 0.402 1.4 0.7 2.7 0.280 
^Adjusted for age, sex, history of CHD, length of hospital stay (days) 
*<0.05, **<0.01, ***<0.001 
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Figure 1: Flowchart of participant recruitment, medical record review and 
major adverse cardiac events 
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Fig 2: Kaplan-Meier survival curves for each derived scale 
 
 
 
